First-Line Treatment of Goodpasture Syndrome
Goodpasture syndrome (anti-GBM disease) is a rare, rapidly progressive autoimmune condition requiring prompt structured treatment. The first-line protocol is designed to eliminate circulating anti-GBM antibodies and halt alveolar hemorrhage before irreversible organ damage occurs.
Treatment Approach
First-line management combines immunosuppressive therapy with plasma exchange — the two-pronged strategy suppresses new anti-GBM antibody production while physically clearing existing antibodies from circulation. Infection prophylaxis may also be considered as part of the regimen.
Full protocol details — including agents, sequencing, and duration — are available in the complete structured regimen.
Clinical Goals
- Clearance of anti-GBM antibodies within 8 weeks
- Recovery from alveolar hemorrhage
References
DOI: 10.1038/kisup.2012.27
- We recommend initiating immunosuppression with cyclophosphamide and glucocorticoids plus plasmapheresis in all patients with anti-GBM GN except those who are treated with dialysis at presentation, have 100% crescents or >50% global glomerulosclerosis in an adequate biopsy sample, and do not have pulmonary hemorrhage.
- Plasma exchange should be performed until anti-GBM titers are no longer detectable.
- As the risk of infection in patients with kidney failure treated with cyclophosphamide is high, prophylaxis of Pneumocystis pneumonia with cotrimoxazole can be considered.
- Antibodies are cleared in most patients treated with plasma exchange combined with immunosuppression within 8 weeks.
- Treatment usually results in recovery from alveolar hemorrhage.
View source ↗